Skip to main content
SpringerLink
Log in

Heart Failure in the Older Hypertensive Patient

  • Chapter
Book cover Hypertension in the Elderly

Part of the book series: Clinical Hypertension and Vascular Diseases ((CHVD))

Abstract

The prevalence of heart failure is 4,900,000 and is rising (1). The prevalence of heart failure progressively increases with aging (Fig. 1). The incidence is 550,000 and approaches 10 per 1000 people after age 65 years. The annual rate for new and recurrent heart events is displayed in Fig. 2. Data from the Framingham Heart Study suggest that the incidence of heart failure has declined in women, but not men (2). At age 40 years, the lifetime risk of developing heart failure is about 20%. Mortality from heart failure is grim, with 20% of patients dying within 1 year (Fig. 3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Heart Association. Heart and Stroke Statistics—2003 Update Dallas, TX: American Heart Association; 2002.

    Google Scholar 

  2. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397–1402.

    Article  PubMed  Google Scholar 

  3. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22(4 suppl A):6A–13A.

    Article  PubMed  CAS  Google Scholar 

  4. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557–1562.

    Article  PubMed  CAS  Google Scholar 

  5. Kannel WB. Vital epidemiologic clues in heart failure. J Clin Epidemiol 2000;53:229–235.

    Article  PubMed  CAS  Google Scholar 

  6. Morbidity and mortality: 2002 Chart Book on cardiovascular, lung, and blood diseases. US Department of Health and Human Services. National Institutes of Health; 2002:90. Available at: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm. October 22, 2003

  7. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001;37:1042–1048.

    Article  PubMed  CAS  Google Scholar 

  8. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001;87:413–419.

    Article  PubMed  CAS  Google Scholar 

  9. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002;137:631–639.

    PubMed  Google Scholar 

  10. Wei JY. Age and the cardiovascular system. N Engl J Med 1992;327:1735–1739.

    Article  PubMed  CAS  Google Scholar 

  11. Hundley WG, Kitzman DW, Morgan TM, et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 2001;38:796–802.

    Article  PubMed  CAS  Google Scholar 

  12. Tresch DD. Signs and symptoms of heart failure in elderly patients. Am J Geriatr Cardiol 1996;5:27–33.

    PubMed  Google Scholar 

  13. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med2001;345:574–581.

    Article  PubMed  CAS  Google Scholar 

  14. Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001;161:2337–2342.

    Article  PubMed  CAS  Google Scholar 

  15. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777–784.

    Article  PubMed  CAS  Google Scholar 

  16. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144–2150.

    Article  PubMed  Google Scholar 

  17. Tresch DD, McGough MF. Heart failure with normal systolic function: a common disorder in older people. J Am Geriatr Soc 1995;43:1035–1042.

    PubMed  CAS  Google Scholar 

  18. Aronow WS. Echocardiography should be performed in all elderly patients with congestive heart failure. J Am Geriatr Soc 1994;42:1300–1302.

    PubMed  CAS  Google Scholar 

  19. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118–2121.

    PubMed  CAS  Google Scholar 

  20. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194–202.

    Article  PubMed  Google Scholar 

  21. Yamamoto K, Wilson DJ, Canzanello VJ, Redfield MM. Left ventricular diastolic dysfunction in patients with hypertension and preserved systolic function. Mayo Clin Proc 2000;75:148–155.

    Article  PubMed  CAS  Google Scholar 

  22. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976–982.

    Article  PubMed  CAS  Google Scholar 

  23. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454–2458.

    Article  PubMed  CAS  Google Scholar 

  24. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509–516.

    PubMed  CAS  Google Scholar 

  25. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587–1593.

    Article  PubMed  CAS  Google Scholar 

  26. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934–1941.

    Article  PubMed  CAS  Google Scholar 

  27. Stanek B, Frey B, Hulsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436–442.

    Article  PubMed  CAS  Google Scholar 

  28. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429–1435.

    Article  Google Scholar 

  29. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293–302.

    Article  Google Scholar 

  30. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685–691.

    Article  Google Scholar 

  31. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312–2318.

    PubMed  CAS  Google Scholar 

  32. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet1999;353:9–13.

    Google Scholar 

  33. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  34. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet1999;353:2001–2007.

    Google Scholar 

  35. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13.

    Article  PubMed  CAS  Google Scholar 

  36. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717.

    Article  PubMed  CAS  Google Scholar 

  37. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–766.

    Article  PubMed  CAS  Google Scholar 

  38. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582–1587.

    Article  PubMed  CAS  Google Scholar 

  39. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan vs captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747–752.

    Article  PubMed  CAS  Google Scholar 

  40. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002;162:1682–1688.

    Article  PubMed  Google Scholar 

  41. Ahmed A. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice. J Am Geriatr Soc 2003;51:123–126.

    Article  PubMed  Google Scholar 

  42. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781.

    Article  PubMed  CAS  Google Scholar 

  43. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003;146:250–257.

    Article  PubMed  Google Scholar 

  44. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517–1525.

    Article  PubMed  CAS  Google Scholar 

  45. Deedwania PC. Angiotensin-converting enzyme inhibitors in congestive heart failure. Arch Intern Med 1990;150:1798–1805.

    Article  PubMed  CAS  Google Scholar 

  46. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101–2113.

    Article  PubMed  CAS  Google Scholar 

  47. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA 1988;259:539–544.

    Article  Google Scholar 

  48. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears in JAMA 1995;274:462]. JAMA 1995;273:1450–1456.

    Article  PubMed  CAS  Google Scholar 

  49. Chen YT, Wang Y, Radford MJ, Krumholz HM. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Am Heart J 2001;141:410–417.

    Article  PubMed  CAS  Google Scholar 

  50. Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic vs diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000;109:605–613.

    Article  PubMed  CAS  Google Scholar 

  51. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993;71:602–604.

    Article  PubMed  CAS  Google Scholar 

  52. Waagstein F, Hjalmarson A, Swedberg K, Wallentin I. Beta blockade in congestive cardiomyopathy. Lancet 1981;2:1115 1116.

    PubMed  Google Scholar 

  53. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441–1446.

    Article  PubMed  CAS  Google Scholar 

  54. Hash TW, Prisant LM. β-B locker use in systolic heart failure and dilated cardiomyopathy. J Clin Pharmacol 1997;37:7–19.

    Article  PubMed  CAS  Google Scholar 

  55. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBISII trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3:469–479.

    Article  PubMed  CAS  Google Scholar 

  56. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–1355.

    Article  PubMed  CAS  Google Scholar 

  57. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659–1667.

    Google Scholar 

  58. Aranda JM, Krause-Steinrauf HJ, Greenberg BH, et al. Comparison of the beta blocker bucindolol in younger vs older patients with heart failure. Am J Cardiol 2002;89:1322–1326.

    Article  PubMed  CAS  Google Scholar 

  59. Aronow WS, Ahn C, Kronzon I. Effect of β blockers alone, of angiotensin-converting enzyme inhibitors alone, and of β blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001;88:1298–1300.

    Article  PubMed  CAS  Google Scholar 

  60. Sin DD, McAlister FA. The effects of β-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 2002;113:650–656.

    Article  PubMed  CAS  Google Scholar 

  61. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649–1654.

    Article  PubMed  CAS  Google Scholar 

  62. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637–645.

    Article  PubMed  CAS  Google Scholar 

  63. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730–1736.

    PubMed  CAS  Google Scholar 

  64. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.

    Article  PubMed  CAS  Google Scholar 

  65. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  66. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  67. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999;5:155–160.

    Article  PubMed  CAS  Google Scholar 

  68. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  69. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414–1421.

    Article  PubMed  CAS  Google Scholar 

  70. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–771.

    Article  PubMed  CAS  Google Scholar 

  71. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–776.

    Article  PubMed  CAS  Google Scholar 

  72. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.

    Article  PubMed  CAS  Google Scholar 

  73. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371–1376.

    Article  PubMed  CAS  Google Scholar 

  74. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689–1697.

    Article  PubMed  CAS  Google Scholar 

  75. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438–441.

    Article  PubMed  CAS  Google Scholar 

  76. Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 2002;90:663–665.

    Article  PubMed  CAS  Google Scholar 

  77. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547–1552.

    Article  PubMed  CAS  Google Scholar 

  78. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303–310.

    Article  PubMed  CAS  Google Scholar 

  79. Cohn JN, Johnson G. Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation 1990;81(2 suppl):III48–III53.

    PubMed  CAS  Google Scholar 

  80. Hughes CV, Wong M, Johnson G, Cohn JN. Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(6 suppl):VI111–VI117.

    PubMed  CAS  Google Scholar 

  81. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999;5:178–187.

    Article  PubMed  CAS  Google Scholar 

  82. Franciosa JA, Taylor AL, Cohn JN, et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002;8:128–135.

    Article  PubMed  Google Scholar 

  83. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525–533.

    Google Scholar 

  84. Rich MW, McSherry F, Williford WO, Yusuf S. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001;38:806–813.

    Article  PubMed  CAS  Google Scholar 

  85. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403–1411.

    Article  PubMed  CAS  Google Scholar 

  86. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871–878.

    Article  PubMed  CAS  Google Scholar 

  87. Shibata MC, Flather MD, Bohm M, et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. Int J Cardiol 2002;86:77–85.

    Article  PubMed  Google Scholar 

  88. Cleland JG, Tendera M, Adamus J, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999;1:211–217.

    Article  PubMed  CAS  Google Scholar 

  89. Pernenkil R, Vinson JM, Shah AS, Beckham V, Wittenberg C, Rich MW. Course and prognosis in patients > or = 70 years of age with congestive heart failure and normal vs abnormal left ventricular ejection fraction. Am J Cardiol 1997;79:216–219.

    Article  PubMed  CAS  Google Scholar 

  90. Aronow WS, Ahn C, Kronzon I. Effect of propranolol vs no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80:207–209.

    Article  PubMed  CAS  Google Scholar 

  91. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990;66:981–986.

    Article  PubMed  CAS  Google Scholar 

  92. Chen CH, Nakayama M, Talbot M, et al. Verapamil acutely reduces ventricular-vascular stiffening and improves aerobic exercise performance in elderly individuals. J Am Coll Cardiol 1999;33:1602–1609.

    Article  PubMed  CAS  Google Scholar 

  93. Warner JG Jr, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999;33:1567–1572.

    Article  PubMed  CAS  Google Scholar 

  94. Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 2003;17:133–139.

    Article  PubMed  CAS  Google Scholar 

  95. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 1994;154:433–437.

    Article  PubMed  CAS  Google Scholar 

  96. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190–1195.

    Article  PubMed  CAS  Google Scholar 

  97. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003;138:10–16.

    PubMed  Google Scholar 

  98. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305–313.

    Article  PubMed  Google Scholar 

  99. Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349–1354.

    Article  PubMed  CAS  Google Scholar 

  100. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212–216.

    Article  PubMed  CAS  Google Scholar 

  101. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension). Lancet 1991;338:1281–1285.

    Article  PubMed  Google Scholar 

  102. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967–1975.

    Google Scholar 

  103. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288:2981–2997.

    Google Scholar 

  104. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients With Hypertension-2 study. Lancet 1999;354:1751–1756.

    Article  PubMed  CAS  Google Scholar 

  105. Diuretic vs α-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension2003;42:239–246.

    Google Scholar 

  106. Mosterd A, D’Agostino RB, Silbershatz H, et al.. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999;340:1221–1227.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension and Clinical Pharmacology, Department of Medicine, Medical College of Georgia, Augusta, GA

    L. Michael Prisant MD, FACC, FACP

  2. Section of Cardiology, Department of Medicine, Medical College of Georgia, Augusta, GA

    Carolyn Landolfo MD, FACC, John Thornton MD, FACC & Vincent J. B. Robinson MBBS, FACC

Authors
  1. L. Michael Prisant MD, FACC, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolyn Landolfo MD, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Thornton MD, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vincent J. B. Robinson MBBS, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical College of Georgia, Augusta, GA

    L. Michael Prisant MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Prisant, L.M., Landolfo, C., Thornton, J., Robinson, V.J.B. (2005). Heart Failure in the Older Hypertensive Patient. In: Prisant, L.M. (eds) Hypertension in the Elderly. Clinical Hypertension and Vascular Diseases. Humana Press. https://doi.org/10.1007/978-1-59259-911-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-911-0_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-197-4

  • Online ISBN: 978-1-59259-911-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation